New combo treatment aims to boost sinus cancer fight
NCT ID NCT05027633
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy and radiation improves outcomes for people with advanced squamous cell cancer in the nasal cavity or sinuses. The goal is to increase the number of patients whose tumors shrink significantly and to improve survival rates compared to historical results with chemotherapy alone. The trial will enroll 35 adults with newly diagnosed, untreated cancer to receive the combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.